TY  - JOUR
AU  - Chudasama, Priya
AU  - Renner, Marcus
AU  - Straub, Melanie
AU  - Mughal, Sadaf S
AU  - Hutter, Barbara
AU  - Kosaloglu-Yalcin, Zeynep
AU  - Schweßinger, Ron
AU  - Scheffler, Matthias
AU  - Alldinger, Ingo
AU  - Schimmack, Simon
AU  - Persigehl, Thorsten
AU  - Kobe, Carsten
AU  - Jäger, Dirk
AU  - von Kalle, Christof
AU  - Schirmacher, Peter
AU  - Beckhaus, Marie-Kristin
AU  - Wolf, Stephan
AU  - Heining, Christoph
AU  - Gröschel, Stefan
AU  - Wolf, Jürgen
AU  - Brors, Benedikt
AU  - Weichert, Wilko
AU  - Glimm, Hanno
AU  - Scholl, Claudia
AU  - Mechtersheimer, Gunhild
AU  - Specht, Katja
AU  - Fröhling, Stefan
TI  - Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
JO  - Clinical cancer research
VL  - 23
IS  - 4
SN  - 1557-3265
CY  - Philadelphia, Pa. [u.a.]
PB  - AACR
M1  - DKFZ-2017-00432
SP  - 962 - 973
PY  - 2017
AB  - Purpose: Altered FGFR1 signaling has emerged as a therapeutic target in epithelial malignancies. In contrast, the role of FGFR1 in soft-tissue sarcoma (STS) has not been established. Prompted by the detection and subsequent therapeutic inhibition of amplified FGFR1 in a patient with metastatic leiomyosarcoma, we investigated the oncogenic properties of FGFR1 and its potential as a drug target in patients with STS.Experimental Design: The frequency of FGFR1 amplification and overexpression, as assessed by FISH, microarray-based comparative genomic hybridization and mRNA expression profiling, SNP array profiling, and RNA sequencing, was determined in three patient cohorts. The sensitivity of STS cell lines with or without FGFR1 alterations to genetic and pharmacologic FGFR1 inhibition and the signaling pathways engaged by FGFR1 were investigated using viability assays, colony formation assays, and biochemical analysis.Results: Increased FGFR1 copy number was detected in 74 of 190 (38.9
LB  - PUB:(DE-HGF)16
C6  - pmid:27535980
DO  - DOI:10.1158/1078-0432.CCR-16-0860
UR  - https://inrepo02.dkfz.de/record/119837
ER  -